--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About STOK20260220C40
Biological Technology
Stoke Therapeutics, Inc., founded in June 2014, was incorporated under the laws of the State of Delaware. The company is an early-stage biopharmaceutical company that has pioneered new ways to treat the underlying causes of serious genetic diseases by precisely up-regulating protein expression. The company is developing novel antisense oligonucleotide (ASO) drugs that target ribonucleic acid or RNA and modulate precursor-messenger RNA or pre-mRNA, up-regulating protein expression to near normal levels with appropriate specificity when needed. The company uses a proprietary technology platform to target enhanced nuclear gene output, or TANGO, to design ASO to up-regulate the expression of proteins in individual patients' genes. The Company's methods are designed to deliver disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or central nervous system, eyes, kidneys and liver, in a highly precise, durable and controllable manner.
